FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia

On July 11, 2017, the Food and Drug Administration granted approval for blinatumomab for the treatment of relapsed or refractory (R/R) precursor B‐cell acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific CD19‐directed CD3 T‐cell engager. The basis for the approval included results from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pulte, E. Dianne, Vallejo, Jonathon, Przepiorka, Donna, Nie, Lei, Farrell, Ann T., Goldberg, Kirsten B., McKee, Amy E., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291336/
https://ncbi.nlm.nih.gov/pubmed/30018129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0179
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados